[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638416":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":22,"responsibleParty":38,"collaborators":7,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":44,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":56,"studyType":57,"phases":7,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":71,"whyStopped":7,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Northern Jiangsu People's Hospital","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Guo-Qing Jiang, MD","Clinical Medical College of Yangzhou University","STUDY_CHAIR",[14,18],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":17},"CONTACT","+8651487373272","jgqing2003@hotmail.com",{"name":19,"role":15,"phone":20,"phoneExt":7,"email":21},"Dou-Sheng Bai, MD","+8651487373372","bdsno1@hotmail.com",[23],{"facility":11,"status":7,"city":24,"state":25,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Yangzhou","Jiangsu","225001","China","CN",{"type":30,"coordinates":31},"Point",[32,33],119.43583,32.39722,{"lat":33,"lon":32},[36,37],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":17},{"name":19,"role":15,"phone":20,"phoneExt":7,"email":21},{"type":39,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Guo-Qing Jiang","Clinical Professor","100638416","effect-of-lsd-on-lipid-profiles-in-cirrhosis-patients-with-portal-hypertension-bleeding-2-year-follow-up-100638416",false,"NCT07588334","Effect of LSD on Lipid Profiles in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)","A Prospective, Single-Center, Observational Cohort Study to Evaluate the Long-Term (2-Year) Effects of Laparoscopic Splenectomy and Azygoportal Disconnection on Lipid Profiles in Patients With Liver Cirrhosis, Portal Hypertension Bleeding.","LSD-LPPH","Inclusion Criteria:\n\n1. Age 18-80 years, male or female\n2. Confirmed diagnosis of liver cirrhosis (clinical, laboratory, imaging)\n3. Splenomegaly and hypersplenism\n4. History of portal hypertension bleeding (esophageal and gastric variceal bleeding )\n5. Child-Pugh Class A or B liver function\n6. Signed written informed consent\n7. Ability to complete 24-month follow-up\n\nExclusion Criteria:\n\n1. Child-Pugh Class C liver cirrhosis\n2. Previous abdominal surgery precluding safe laparoscopic splenectomy and azygoportal disconnection\n3. Severe cardiac, pulmonary, cerebrovascular dysfunction; malignant tumors; primary hematological disorders\n4. Metabolic\u002Fendocrine diseases: Familial hyperlipidemia; uncontrolled severe diabetes mellitus, thyroid dysfunction, nephrotic syndrome; use of lipid-lowering drugs, hormones, or other drugs affecting blood lipids within 1 month before surgery.\n5. Infections\u002Finflammatory diseases: Active hepatitis, severe infections, or autoimmune diseases.\n6. Cirrhotic complications (hepatic encephalopathy, refractory ascites) within 1 month before surgery\n7. Pregnancy or lactation\n8. Poor compliance, inability to complete follow-up","ALL","18 Years","80 Years",{"count":54,"type":55},30,"ESTIMATED","2 Years","OBSERVATIONAL","Patients with liver cirrhosis frequently exhibit dyslipidemia due to impaired hepatic lipid synthesis, altered bile acid metabolism, and portal hypertension. Laparoscopic Splenectomy and Azygoportal Disconnection (LSD) is commonly used to treat Cirrhosis with Portal Hypertension Bleeding in these patients, but its impact on lipid profiles over 2 years remains poorly characterized. This study will follow patients undergoing LSD to measure changes in serum lipid parameters before and after surgery, identify risk factors for lipid profile deterioration or improvement, and determine whether LSD can ameliorate dyslipidemia in the long term, thereby informing metabolic management strategies in cirrhotic patients.",[60,61,62,63],"Cirrhosis, Liver","Splenectomy; Status","Portal Hypertension","Lipid Profiles",[65,66,67,63,68,69,70],"Cirrhosis","Splenectomy","Laparoscopy","azygoportal disconnection","Portal Hypertension Bleeding","hypersplenism","NOT_YET_RECRUITING","2026-05-10",{"date":74,"type":75},"2026-05-14","ACTUAL",{"date":77,"type":55},"2026-05-01",{"date":79,"type":55},"2029-02-28",{"name":5,"class":6},1]